Skip to content

Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Ceftriaxone in craniocerebral injury

Under the guidance of TDM to study the effect of ARC on the plasma concentration of three broad-spectrum antibiotics in patients with craniocerebral injury in ICU and its mechanism

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021347
Enrollment
Unknown
Registered
2019-02-16
Start date
2019-02-15
Completion date
Unknown
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

craniocerebral injury

Interventions

ARC:NO Intervention
n-ARC:NO Intervention

Sponsors

First Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. Brain injury (including patients with craniocerebral trauma and/or brain surgery); 3. Patients with intracranial and/or pulmonary infections who require anti-infective treatment by ceftriaxone; 4. Patients with central venous catheters and arterial catheters; 5. Serum creatinine is within the normal range or below the lower limit of the normal range; 6. The patient or his legal representative signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Combine with cardiac insufficiency; 2. Shortage of treatment funding and estimated to be unable to complete treatment; 3. Serious electrolyte imbalance (such as hyperkalemia) requires CRRT treatment; 4. Need to supplement blood products (especially plasma) >1000mL or more; 5. Coexisting abdominal compartment syndrome; 6. Renal insufficiency (eGFR calculated according to the CG formula 30kg/m2; 11. Hb<70g/L.

Design outcomes

Primary

MeasureTime frame
probability of PK/PD target attainment(50%fT>MIC and 100%fT>MIC);

Secondary

MeasureTime frame
Half life (T1/2);Clearance (Cl);Change in urinary clearance of unchanged ceftriaxone;

Countries

china

Contacts

Public ContactJian Liu
541885464@qq.com+86 13609354197

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026